552330-86-6

Basic information

• Product Name: 5-BROMO-2,3-DIHYDRO-ISOINDOL-1-ONE
• Synonyms: 5-BROMO-2,3-DIHYDRO-ISOINDOL-1-ONE;5-BroMo-1-isoindolinone, 96%;5-BroMo-2,3-dihydro-1H-isoindol-1-one;4-BroMo-2,3-dihydroisoindol-1-one;5-BroMo-1-oxo-isoindoline;1H-Isoindol-1-one, 5-broMo-2,3-dihydro-;5-Bromo-2,3-dihydro-1-oxo-1H-isoindole;5-Bromoisoindolin-1-one≥ 98%(GC)
• CAS NO: 552330-86-6
• Molecular Formula: C₈H₆BrNO
• Molecular Weight: 212.05
• Mol File: 552330-86-6.mol
• Article Data: 24

Chemical Properties

• Melting Point: 267 °C
• Boiling Point: 448.367 °C at 760 mmHg
• Flash Point: 224.965 °C
• Appearance: /
• Density: 1.666 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.625
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.75±0.20(Predicted)
• CAS DataBase Reference: 5-BROMO-2,3-DIHYDRO-ISOINDOL-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2,3-DIHYDRO-ISOINDOL-1-ONE(552330-86-6)
• EPA Substance Registry System: 5-BROMO-2,3-DIHYDRO-ISOINDOL-1-ONE(552330-86-6)

Safety Data

• Hazardous Substances Data: 552330-86-6(Hazardous Substances Data)

Usage

Chemical Properties

Pink Solid

InChI:InChI=1/C8H6BrNO/c9-6-1-2-7-5(3-6)4-10-8(7)11/h1-3H,4H2,(H,10,11)

Upstream product

• 194487-79-1 methyl 4-bromo-2-ethylbenzoate 
• 1972-28-7 diethylazodicarboxylate 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 
• 78471-43-9 methyl 4-bromo-2-(bromomethyl)benzoate 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 644984-78-1 4-bromo-2-ethylbenzoic acid 
• 201230-82-2 carbon monoxide 
• 10269-01-9 3-bromobenzylamine 

Downstream Products

• 926307-72-4 methyl 1-oxo-2,3-dihydro-1H-isoindole-5-carboxylate 
• 23386-40-5 1-oxo-2,3-dihydro-1H-isoindole-5-carboxylic acid 
• 1613639-03-4 2-[5-(1-oxo-2,3-dihydro-1H-isoindol-5-yl)pyridin-3-ylamino]-2-phenylacetamide 
• 1567837-01-7 2,4-difluoro-N-(5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)benzamide 
• 1567836-94-5 5-(5-(3-aminophenyl)thiophen-2-yl)-2-methylisoindolin-1-one 
• 1567837-79-9 4-fluoro-N-((5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)carbamothioyl)benzamide 
• 1567836-38-7 2,4-difluoro-N-(5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)benzenesulfonamide 
• 868066-91-5 5-bromo-2-methyl-1,3-dihydroisoindol-1-one 
• 1357104-66-5 C₃₆H₄₄N₂O₅ 

Relevant articles and documents

Discovery of Brain-Penetrant Glucosylceramide Synthase Inhibitors with a Novel Pharmacophore

Inhibition of glucosylceramide synthase (GCS) is a major therapeutic strategy for Gaucher’s disease and has been suggested as a potential target for treating Parkinson’s disease. Herein, we report the discovery of novel brain-penetrant GCS inhibitors. Assessment of the structure-activity relationship revealed a unique pharmacophore in this series. The lipophilic ortho-substituent of aromatic ring A and the appropriate directionality of aromatic ring B were key for potency. Optimization of the absorption, distribution, metabolism, elimination, toxicity (ADMETox) profile resulted in the discovery of T-036, a potent GCS inhibitor in vivo. Pharmacophore-based scaffold hopping was performed to mitigate safety concerns associated with T-036. The ring opening of T-036 resulted in another potent GCS inhibitor with a lower toxicological risk, T-690, which reduced glucosylceramide in a dose-dependent manner in the plasma and cortex of mice. Finally, we discuss the structural aspects of the compounds that impart a unique inhibition mode and lower the cardiovascular risk.

Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase

Aberrant activity of the histone methyltransferase polycomb repressive complex 2 (PRC2) has been linked to several cancers, with small-molecule inhibitors of the catalytic subunit of the PRC2 enhancer of zeste homologue 2 (EZH2) being recently approved fo

Degradable hydrogel under physiological conditions

The present invention discloses a hydrogel that can be degraded under physiological conditions. The hydrogel includes at least one backbone moiety and an optional crosslinking moiety, and biodegradable linkers connecting backbone moieties and crosslinking moieties can be degraded by intramolecular cyclization.